文献速递基础与转化研究新药、器械与细胞基因治疗研发

BCL11A干扰联合截短型促红细胞生成素受体实现持续性胎儿血红蛋白诱导

Sustained fetal hemoglobin induction in vivo is achieved by BCL11A interference and coexpressed truncated erythropoietin receptor.
PubMed 文献 · Sci Transl Med · 2021-01-01

该研究开发了红系特异性表达截短型人促红细胞生成素受体(thEpoR)和靶向BCL11A的shmiR的慢病毒载体,在异种移植小鼠和恒河猴自体移植模型中比较thEpoR/shmiR BCL11A与单用shmiR BCL11A的效果,发现thEpoR可增强并维持HbF诱导,恒河猴中HbF持续在20%至25%达4至8个月。

要点

  • thEpoR与shmiR BCL11A共表达可增强红系细胞生成并维持HbF诱导。
  • 单用shmiR BCL11A的HbF诱导强劲但短暂。
  • 恒河猴中thEpoR/shmiR BCL11A使HbF持续在20%至25%达4至8个月。

核心结论

  • thEpoR与shmiR BCL11A共表达可在异种移植小鼠和恒河猴中增强并维持胎儿血红蛋白诱导。
  • 该策略可能成为血红蛋白病的可行基因治疗策略。

研究设计与样本

  • 研究在异种移植小鼠和恒河猴自体移植模型中比较thEpoR/shmiR BCL11A与单用shmiR BCL11A修饰的CD34+细胞。
  • thEpoR通过从羧基末端删除40个氨基酸生成,载体由红系特异性启动子驱动。

主要发现

  • thEpoR表达在体外增强了基因修饰细胞的红系生成。
  • thEpoR增强了shmiR BCL11A介导的HbF诱导,而单用shmiR BCL11A的HbF诱导强劲但短暂。
  • 恒河猴中thEpoR/shmiR BCL11A共表达使HbF持续在20%至25%达4至8个月。

临床怎么用

  • 该载体策略可能为血红蛋白病基因治疗提供持续性HbF诱导的新思路。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Hematopoietic stem cell gene therapy for hemoglobin disorders, including sickle cell disease, requires high-efficiency lentiviral gene transfer and robust therapeutic globin expression in erythroid cells. Erythropoietin is a key cytokine for erythroid proliferation and differentiation (erythropoiesis), and truncated human erythropoietin receptors (thEpoR) have been reported in familial polycythemia. We reasoned that coexpression of thEpoR could enhance the phenotypic effect of a therapeutic vector in erythroid cells in xenograft mouse and autologous nonhuman primate transplantation models. We generated thEpoR by deleting 40 amino acids from the carboxyl terminus, allowing for erythropoietin-dependent enhanced erythropoiesis of gene-modified cells. We then designed lentiviral vectors encoding both thEpoR and B cell lymphoma/leukemia 11A (BCL11A)-targeting microRNA-adapted short hairpin RNA (shmiR BCL11A) driven by an erythroid-specific promoter. thEpoR expression enhanced erythropoiesis among gene-modified cells in vitro. We then transplanted lentiviral vector gene-modified CD34+ cells with erythroid-specific expression of both thEpoR and shmiR BCL11A and compared to cells modified with shmiR BCL11A only. We found that thEpoR enhanced shmiR BCL11A-based fetal hemoglobin (HbF) induction in both xenograft mice and rhesus macaques, whereas HbF induction with shmiR BCL11A only was robust, yet transient. thEpoR/shmiR BCL11A coexpression allowed for sustained HbF induction at 20 to 25% in rhesus macaques for 4 to 8 months. In summary, we developed erythroid-specific thEpoR/shmiR BCL11A-expressing vectors, enhancing HbF induction in xenograft mice and rhesus macaques. The sustained HbF induction achieved by addition of thEpoR and shmiR BCL11A may represent a viable gene therapy strategy for hemoglobin disorders.

来源:Sci Transl Med,查看原文。版权归原作者所有。

引用

  1. Uchida N, Ferrara F, Drysdale CM, et al. Sustained fetal hemoglobin induction in vivo is achieved by BCL11A interference and coexpressed truncated erythropoietin receptor. Sci Transl Med. 2021. PMID: 33910976. doi:10.1126/scitranslmed.abb0411

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。